Our Business

Phosphagenics Limited is a Melbourne-based biotechnology company which has developed a unique delivery technology based on tocopherol phosphate (Vitamin E phosphate).  This platform technology, known as TPM® is able to deliver actives and drugs into or through the skin.

Phosphagenics shares are listed on the Australian Securities Exchange (ASX: POH).  Phosphagenics ADR’s are also traded on the OTCQX in the USA.


Breaking News

11 July 2014


  • Includes $3 million Share Purchase Plan
  • Upcoming opioid pain patch trials fully funded
Phosphagenic Limited has raised $19.3 million via a placement of $16.3 million to insitutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SPP) to be offered to existing shareholders.  The placement of $16.3 million will be made in two tranches.

"This capital raising positions us strongly to fulfil our commercialisation objectives and fully funds our scheduled TPM®/opiod clinical trial programs.  The capital raised is earmarked for our pivotal TPM®/Oxymorphone Phase 2 clinical trial in the USA scheduled for the first half of 2015 and our upcoming TPM®/Oxycodone Phase 2 trial in Australia," said CEO, Harry Rosen.

21 May 2014


  • Rapid and effective relief for all racehorses in study
  • Positive implications for upcoming Phase 2 TPM®/Oxycodone trial

A Phosphagenics study using its TPM®/Oxycodone topical patch to manage shin soreness pain for thoroughbed racehorses found recovery from pain in all horses within 1-2 days.

The study was conducted on six thoroughbreds, between two and three years of age, exhibiting cannon (shin) bone soreness arising from injuries in either one or two limbs, with a patch applied daily to each injured limb for ten days.